Back to top
more

Merck & Co. (MRK)

(Delayed Data from NYSE)

$116.60 USD

116.60
8,364,945

+0.05 (0.04%)

Updated Aug 23, 2024 04:00 PM ET

After-Market: $116.55 -0.05 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth D Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Merck (MRK) Q4 Earnings Beat, Sales Miss, Upbeat '24 View

by Zacks Equity Research

Merck (MRK) beats Q4 estimates for earnings but misses the mark on sales. The company issues an encouraging 2024 guidance. Stock rises in pre-market.

Merck (MRK) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Merck (MRK) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Merck (MRK) Beats Q4 Earnings Estimates

by Zacks Equity Research

Merck (MRK) delivered earnings and revenue surprises of 133.33% and 0.45%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Mark Vickery headshot

Powell Dubious on March Cut, Markets Slide

by Mark Vickery

Indices jumped higher on the Fed's release initially, but in terms of forecasting a March cut, Fed Chair Powell said that this was "not the most-likely case."

AbbVie (ABBV) to Report Q4 Earnings: What's in the Cards?

by Zacks Equity Research

AbbVie's (ABBV) Q4 performance will likely reflect its newer immunotherapy drugs trying to compensate for declining Humira sales following the loss of U.S. exclusivity.

Pfizer (PFE) Surpasses Q4 Earnings Estimates

by Zacks Equity Research

Pfizer (PFE) delivered earnings and revenue surprises of 152.63% and 0.80%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

GSK Gears Up for Q4 Earnings: Will It Surpass Estimates?

by Zacks Equity Research

We expect GSK's specialty products like Arexvy, Cabenuva, Dovato, Bexsero, Trelegy Ellipta and Shingrix to drive fourth-quarter sales performance.

Countdown to Merck (MRK) Q4 Earnings: Wall Street Forecasts for Key Metrics

by Zacks Equity Research

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Merck (MRK), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2023.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Merck (MRK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the closing of the recent trading day, Merck (MRK) stood at $120.82, denoting a +0.57% change from the preceding trading day.

Earnings Preview: AbbVie (ABBV) Q4 Earnings Expected to Decline

by Zacks Equity Research

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can Moderna's (MRNA) Launches Reduce COVID Sales Dependency?

by Zacks Equity Research

With COVID-19 vaccine sales declining, Moderna (MRNA) is accelerating the development of its non-COVID pipeline. It is gearing up for potential product launches over the next five years.

What You Need to Know Ahead of Bristol-Myers (BMY) Q4 Earnings

by Zacks Equity Research

Investors are likely to focus on Opdivos demand, along with an incremental contribution from newer drugs, when Bristol-Myers (BMY) reports Q4 results.

Merck (MRK) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release

by Zacks Equity Research

Merck (MRK) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar

by Zacks Equity Research

Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.

Novartis (NVS) to Report Q4 Earnings: Is a Beat in Store?

by Zacks Equity Research

Novartis' (NVS) key drugs, Entresto, Kisqali and Pluvicto, are likely to have fueled its top and bottom-line numbers in the fourth quarter.

Can Merck (MRK) Keep the Beat Streak Alive in Q4 Earnings?

by Zacks Equity Research

Investor focus is likely to be on the sales of Merck's (MRK) blockbuster oncology medicine, Keytruda, when the company reports fourth-quarter earnings.

Sheraz Mian headshot

Q4 Earnings Season Scorecard and Fresh Analyst Reports for Amazon, Home Depot & Merck

by Sheraz Mian

Today's Research Daily features a real-time update on the Q4 earnings season and updated reports on Amazon (AMZN), Home Depot (HD), Merck (MRK) & others.

Merck (MRK) Laps the Stock Market: Here's Why

by Zacks Equity Research

Merck (MRK) concluded the recent trading session at $119.43, signifying a +0.45% move from its prior day's close.

Merck (MRK) Stock Moves -0.12%: What You Should Know

by Zacks Equity Research

The latest trading day saw Merck (MRK) settling at $118.49, representing a -0.12% change from its previous close.

Is it a Good Idea to Buy Fusion Pharmaceuticals (FUSN) Stock Now?

by Zacks Equity Research

Here, we discuss some reasons why investing in Fusion Pharmaceuticals (FUSN) stock now may turn out to be a prudent move.

Merck (MRK) Keytruda Ok'd by FDA for Expanded Cervical Cancer Use

by Zacks Equity Research

FDA approves Merck's (MRK) Keytruda plus chemoradiotherapy (CRT) for patients with FIGO 2014 Stage III-IVA cervical cancer based on data from the phase KEYNOTE-A18 study.

Kinjel Shah headshot

Pharma Stock Roundup: MRK to Buy Harpoon, JNJ to Acquire Ambrx Biopharma & More

by Kinjel Shah

Merck (MRK) offers to acquire Harpoon for $680 million. J&J (JNJ) is set to acquire Ambrx Biopharma for approximately $2.0 billion

C4 (CCCC) Up 6% on Restructuring Plan to Curb Cash Burn

by Zacks Equity Research

The new restructuring plan will allow C4 Therapeutics (CCCC) to extend its cash runway into 2027. The company plans to reduce its workforce by nearly 30%.

Is Vident U.S. Equity Strategy ETF (VUSE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for VUSE